Mild Cognitive Impairment Clinical Trial
Official title:
Risk Evaluation and Education for Alzheimer's Disease (REVEAL) IV
This study is intended to examine the impact of receiving a genetic risk assessment for Alzheimer's disease (AD) among individuals with Mild Cognitive Impairment (MCI).
Alzheimer's disease is a common condition affecting memory and thinking. Genes can sometimes
be used to provide risk estimates for the eventual development of certain common diseases.
Apolipoprotein E (APOE) is one gene which can provide information about a person's chances of
developing Alzheimer's disease.
Some people with a diagnosis of Mild Cognitive Impairment (MCI) are curious to learn more
about the chance of developing Alzheimer's disease. In the REVEAL IV Study, we are examining
the psychological and behavioral impact of learning genetic risk information pertaining to
the chance for an individual with MCI to progress to dementia of the Alzheimer's type within
three years.
Participation in this study requires an initial phone call which will elicit some demographic
information about the participant and his or her study partner. A first in-person visit to
the research clinic will consist of an education session, the administration of knowledge and
attitudinal surveys and some tests to assess memory and thinking skills. This visit will take
approximately 2-3 hours. Participants with MCI will have their blood drawn for genetic
testing. Participants will then be randomized to one of two groups. Those in the intervention
arm will receive a three-year risk estimate for the chance of progressing to dementia of the
Alzheimer's type based on age, the diagnosis of MCI and their own APOE gene test result.
Those in the comparison arm will receive a three-year risk estimate for the chance of
progressing to dementia of the Alzheimer's type based on age and the diagnosis of MCI,
without the APOE gene test result. Participants randomized to the comparison arm will have
the opportunity to learn their own APOE gene test result at the end of the study.
Participants and their study partners will be followed for 6 months following disclosure of
results with 1 additional clinic visit and 1 additional phone interviews.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04513106 -
Promoting Advance Care Planning for Persons With Early-stage Dementia in the Community: a Feasibility Trial
|
N/A | |
Recruiting |
NCT06011681 -
The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
|
||
Recruiting |
NCT04522739 -
Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease
|
Phase 4 | |
Active, not recruiting |
NCT03167840 -
Falls Prevention Through Physical And Cognitive Training in Mild Cognitive Impairment
|
N/A | |
Active, not recruiting |
NCT03676881 -
Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
|
||
Not yet recruiting |
NCT05041790 -
A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate Compared to Placebo in Patients With Degenerative Mild Cognitive Impairment
|
Phase 4 | |
Recruiting |
NCT04121156 -
High Definition Transcranial Direct Current Stimulation (HD-tDCS) in Patients With Mild Cognitive Impairment
|
N/A | |
Recruiting |
NCT03605381 -
MORbidity PRevalence Estimate In StrokE
|
||
Completed |
NCT02774083 -
Cognitive Training Using Feuerstein Instrumental Enrichment
|
N/A | |
Completed |
NCT01315639 -
New Biomarker for Alzheimer's Disease Diagnostic
|
N/A | |
Enrolling by invitation |
NCT06023446 -
Can (Optical Coherence Tomography) Pictures of the Retina Detect Alzheimer's Disease at Its Earliest Stages?
|
||
Completed |
NCT04567745 -
Automated Retinal Image Analysis System (EyeQuant) for Computation of Vascular Biomarkers
|
Phase 1 | |
Recruiting |
NCT05579236 -
Cortical Disarray Measurement in Mild Cognitive Impairment and Alzheimer's Disease
|
||
Completed |
NCT03583879 -
Using Gait Robotics to Improve Symptoms of Parkinson's Disease
|
N/A | |
Terminated |
NCT02503501 -
Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease
|
Phase 2 | |
Not yet recruiting |
NCT03740178 -
Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005)
|
Phase 1 | |
Active, not recruiting |
NCT05204940 -
Longitudinal Observational Biomarker Study
|
||
Recruiting |
NCT02663531 -
Retinal Neuro-vascular Coupling in Patients With Neurodegenerative Disease
|
N/A | |
Recruiting |
NCT06150352 -
Sleep Apnea, Neurocognitive Decline and Brain Imaging in Patients With Subjective or Mild Cognitive Impairment
|
||
Recruiting |
NCT03507192 -
Effects of Muscle Relaxation on Cognitive Function in Patients With Mild Cognitive Impairment and Early Stage Dementia.
|
N/A |